Phase I and pharmacokinetic study of trabectedin as a 1- or 3-hour infusion weekly in patients with advanced solid malignancies

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3591-3599

  Forouzesh, Bahram ^a   Hidalgo, Manuel ^a   Chu, Quincy ^a   Mita, Alain ^a   Mita, Monica ^a   Schwartz, Garry ^b   Jimeno, José ^c,d   Gómez, Javier ^c   Alfaro, Vicente ^c   Lebedinsky, Claudia ^c   Zintl, Patrik ^c   Rowinsky, Eric K ^a,e  

^a CTRC Institute for Drug Development   (United States)

^b BROOKE ARMY MEDICAL CENTER   (United States)

^c PHARMAMAR S A   (Spain)

^d INSTITUT UNIVERSITARI DEXEUS   (Spain)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CHLORMETHINE DERIVATIVE; CREATINE KINASE; FOLIC ACID; LOMETREXOL; TEMOZOLOMIDE; TRABECTEDIN;

ABDOMINAL DISTENSION; ABDOMINAL PAIN; ADRENAL CANCER; ADULT; ADVANCED CANCER; AGED; AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTICLE; BONE CANCER; BRAIN CANCER; BREAST CANCER; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONSTIPATION; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG INFUSION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSGEUSIA; DYSPNEA; FATIGUE; FEMALE; FEVER; FIBROSARCOMA; GERM CELL TUMOR; HUMAN; HUMAN CELL; HUMAN TISSUE; INJECTION SITE REACTION; LEIOMYOSARCOMA; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYALGIA; MYXOSARCOMA; NAUSEA; NECK PAIN; NEUTROPENIA; OSTEOSARCOMA; OVARY CANCER; OVARY CARCINOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; RHABDOMYOLYSIS; SIDE EFFECT; SOFT TISSUE SARCOMA; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; THROMBOPHLEBITIS; UTERUS CANCER; UTERUS LEIOMYOSARCOMA; VOMITING;

ADULT; AGED; ANEMIA; ANTINEOPLASTIC AGENTS, ALKYLATING; AREA UNDER CURVE; CREATINE KINASE; DIOXOLES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FATIGUE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LEUKOPENIA; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; NEOPLASMS; TETRAHYDROISOQUINOLINES; TRANSAMINASES; YOUNG ADULT;

EID: 66149170084     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2889     Document Type: Article

References (28)

1. Pommier Y, Kohlhagen G, Bailly C, Waring M, Mazumder A, Kohn KW. DNA sequence- and structure-selective alkylation of guanine N2 in the DNA minor groove by ecteinascidin 743, a potent antitumor compound from the Caribbean tunicate Ecteinascidia turbinata. Biochemistry 1996;35:13303-13309 (Pubitemid 26349423)
2. Martinez N, Sanchez-Beato M, Carnero A, et al. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients. Mol Cancer Ther 2005;4:814-823 (Pubitemid 40767126)
3. Erba E, Bergamaschi D, Bassano L, et al. Ecteinascidin- 743 (ET-743), a natural marine compound, with a unique mechanism of action. Eur J Cancer 2001;37:97-105. (Pubitemid 32119366)
4. Martinez EJ, Corey EJ, Owa T. Antitumor activity- and gene expression-based profiling of ecteinascidin Et 743 and phthalascidin Pt 650. Chem Biol 2001;8:1151-1160 (Pubitemid 34029884)
5. Carter NJ, Keam SJ. Trabectedin: a review of its use in the management of soft tissue sarcoma and ovarian cancer. Drugs 2007;67:2257-2276
6. van Kesteren C, Twelves C, Bowman A, et al. Clinical pharmacology of the novel marine-derived anticancer agent Ecteinascidin 743 administered as a 1- and 3-h infusion in a phase I study. Anticancer Drugs 2002;13:381-393 (Pubitemid 34454724)
7. Twelves C, Hoekman K, Bowman A, et al. Phase I and pharmacokinetic study of Yondelis (Ecteinascidin-743; ET-743) administered as an infusion over 1 h or 3 h every 21 days in patients with solid tumours. Eur J Cancer 2003; 39:1842-1851. (Pubitemid 37311179)
8. van Kesteren C, Cvitkovic E, Taamma A, et al. Pharmacokinetics and pharmacodynamics of the novel marine-derived anticancer agent ecteinascidin 743 in a phase I dose-finding study. Clin Cancer Res 2000;6:4725-4732 (Pubitemid 32110411)
9. Taamma A, Misset JL, Riofrio M, et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24- hour continuous infusion in patients with solid tumors. J Clin Oncol 2001;19:1256-1265 (Pubitemid 32202528)
10. Ryan DP, Supko JG, Eder JP, et al. Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies. Clin Cancer Res 2001;7:231-242 (Pubitemid 32183024)
11. Villalona-Calero MA, Eckhardt SG, Weiss G, et al. A phase I and pharmacokinetic study of ecteinascidin- 743 on a daily x 5 schedule in patients with solid malignancies. Clin Cancer Res 2002;8: 75-85. (Pubitemid 34101461)
12. Le Cesne A, Blay JY, Judson I, et al. Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol 2005;23:576-584 (Pubitemid 46224235)
13. Yovine A, Riofrio M, Blay JY, et al. Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J Clin Oncol 2004;22:890-899 (Pubitemid 41103601)
14. Garcia-Carbonero R, Supko JG, Maki RG, et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 2005;23:5484-5492 (Pubitemid 46300141)
15. Garcia-Carbonero R, Supko JG, Manola J, et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 2004;22:1480-1490 (Pubitemid 41103631)
16. Le Cesne A, von Mehren M, Chawla S, et al. Assessing the clinical impact of trabectedin in patients with leiomyosarcomas or liposarcomas (L-sarcomas) progressing despite prior conventional chemotherapy: clinical benefit rate, growth modulation index and tumor variation as parameters of treatment effect in a randomised international trial of two trabectedin dosing regimens. Eur J Cancer 2007;5:405, (abstract 7512).
17. National Cancer Institute. Guidelines for the reporting of adverse drug reactions. MD, Division of Cancer Treatment, National Cancer Institute 1999:1-80.
18. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-214 (Pubitemid 11167383)
19. Brandon EF, Sparidans RW, Guijt KJ, et al. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET- 743 (Yondelis, Trabectidin), a novel marine anti- cancer drug. Invest New Drugs 2006;24:3-14.
20. Rivory LP, Watkins PB. Erythromycin breath test. Clin Pharmacol Ther 2001;70:395-399 (Pubitemid 33022481)
21. Schoffski P, Wolter P, Clement P, et al. Trabectedin (ET-743): evaluation of its use in advanced soft-tissue sarcoma. Future Oncol 2007;3:381-392 (Pubitemid 47250154)
22. Chawla SP, Casali PG, von Mehren M, et al. Clinical tolerability of trabectedin administered by two different schedules (weekly for 3 of 4 weeks vs q3 weeks) in patients with advanced metastatic liposarcoma or leiomyosarcoma (Lsarcomas) progressing despite prior treatment with at least anthracycline and ifosfamide. Eur J Cancer 1997;Suppl Vol 5, No.4:407, (Poster 7517).
23. Krasner CN, McMeekin DS, Chan S, et al. A Phase II study of trabectedin single agent in patients with recurrent ovarian cancer previously treated with platinum-based regimens. Br J Cancer 2007;97:1618-1624 (Pubitemid 350249358)
24. Schoffski P, Dumez H, Wolter P, et al. Clinical impact of trabectedin (ecteinascidin-743) in advanced/ metastatic soft tissue sarcoma. Expert Opin Pharmacother 2008;9:1609-1618
25. Demetri GD, Schuetze S, le Cesne A, et al. Impact of independent review on efficacy outcomes in a randomised multicenter trial of trabectedin given by two dosing regimens in patients (pts) with progressing leiomyosarcomas or liposarcomas (L-sarcomas). Eur J Cancer 2007;5:402, (Poster 7500).
26. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal endpoint for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002;38:543-549 (Pubitemid 34185394)
27. Perez-Ruixo JJ, Zannikos P, Hirankarn S, et al. Population pharmacokinetic meta-analysis of trabectedin (ET-743, Yondelis) in cancer patients. Clin Pharmacokinet 2007;46:867-884 (Pubitemid 47443311)
28. Hemeryck A, Vermeir M, Cuyckens F. In vitro studies on the hepatic metabolism of trabectedin in man and monkey and assessment of trabectedin's human CYP inhibition potential. Drug Metabolism Reviews 2006;38:103, abstract 36. 9th ISSX Meeting, Manchester.